These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

304 related items for PubMed ID: 1873776

  • 1. A phase I, II study of high-dose 5-fluorouracil and high-dose leucovorin with low-dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies.
    Ardalan B, Sridhar KS, Benedetto P, Richman S, Waldman S, Morrell L, Feun L, Savaraj N, Fodor M, Livingstone A.
    Cancer; 1991 Sep 15; 68(6):1242-6. PubMed ID: 1873776
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. A phase I study of continuous infusion 5-fluorouracil plus calcium leucovorin in combination with N-(phosphonacetyl)-L-aspartate in metastatic gastrointestinal adenocarcinoma.
    Grem JL, McAtee N, Steinberg SM, Hamilton JM, Murphy RF, Drake J, Chisena T, Balis F, Cysyk R, Arbuck SG.
    Cancer Res; 1993 Oct 15; 53(20):4828-36. PubMed ID: 8402669
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. N-(phosphonacetyl)-L-aspartate and calcium leucovorin modulation of fluorouracil administered by constant rate and circadian pattern of infusion over 72 hours in metastatic gastrointestinal adenocarcinoma.
    Grem JL, Yee LK, Schuler B, Hamilton JM, Chen AP, Chabuk C, Grollman F, Grabenc M, Allegra CJ, Takimoto CH.
    Ann Oncol; 2001 Nov 15; 12(11):1581-7. PubMed ID: 11822758
    [Abstract] [Full Text] [Related]

  • 9. Fluorouracil modulation in colorectal cancer: lack of improvement with N -phosphonoacetyl- l -aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule--an Eastern Cooperative Oncology Group/Cancer and Leukemia Group B Study.
    O'Dwyer PJ, Manola J, Valone FH, Ryan LM, Hines JD, Wadler S, Haller DG, Arbuck SG, Weiner LM, Mayer RJ, Benson AB.
    J Clin Oncol; 2001 May 01; 19(9):2413-21. PubMed ID: 11331320
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A phase II pilot study of high-dose 24-hour continuous infusion of 5-FU and leucovorin and low-dose PALA for patients with colorectal cancer: a Southwest Oncology Group study.
    Whitehead RP, Benedetti JK, Abbruzzese JL, Ardalan B, Williamson S, Gaynor ER, Balcerzak SP, Macdonald JS.
    Invest New Drugs; 2004 Nov 01; 22(4):467-73. PubMed ID: 15292717
    [Abstract] [Full Text] [Related]

  • 12. Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine ribonucleoside (MMPR), and leucovorin in patients with advanced cancer.
    Hageboutros A, Hudes GR, Greene F, LaCreta FP, Brennan J, O'Dwyer PJ.
    Invest New Drugs; 1997 Nov 01; 15(2):139-45. PubMed ID: 9220293
    [Abstract] [Full Text] [Related]

  • 13. Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine riboside: optimization of 6-methylmercaptopurine riboside dose and schedule through biochemical analysis of sequential tumor biopsy specimens.
    O'Dwyer PJ, Hudes GR, Colofiore J, Walczak J, Hoffman J, LaCreta FP, Comis RL, Martin DS, Ozols RF.
    J Natl Cancer Inst; 1991 Sep 04; 83(17):1235-40. PubMed ID: 1714507
    [Abstract] [Full Text] [Related]

  • 14. Phase I study of N-(phosphonacetyl)-L-aspartate with fluorouracil and with or without dipyridamole in patients with advanced cancer.
    Fleming RA, Capizzi RL, Muss HB, Smith S, Fernandes DJ, Homesley H, Loggie BW, Case L, Morris R, Russell GB, Richards F.
    Clin Cancer Res; 1996 Jul 04; 2(7):1107-14. PubMed ID: 9816275
    [Abstract] [Full Text] [Related]

  • 15. Biochemical modulation of bolus fluorouracil by PALA in patients with advanced colorectal cancer.
    Kemeny N, Conti JA, Seiter K, Niedzwiecki D, Botet J, Martin D, Costa P, Wiseberg J, McCulloch W.
    J Clin Oncol; 1992 May 04; 10(5):747-52. PubMed ID: 1569447
    [Abstract] [Full Text] [Related]

  • 16. A phase I-II study of N-(phosphonacetyl)-L-aspartic acid (PALA) added to 5-fluorouracil and folinic acid in advanced colorectal cancer.
    Jodrell DI, Oster W, Kerr DJ, Canney PA, Yosef H, Steward WP, Kaye SB, Cassidy J.
    Eur J Cancer; 1994 May 04; 30A(7):950-5. PubMed ID: 7946590
    [Abstract] [Full Text] [Related]

  • 17. Sequential biochemical modulation of fluorouracil with folinic acid, N-phosphonacetyl-L-aspartic acid, and interferon alfa-2a in advanced colorectal cancer.
    Royce ME, McGarry W, Bready B, Dakhil SR, Belt RJ, Goodwin JW, Gray R, Hoff PM, Winn R, Pazdur R.
    J Clin Oncol; 1999 Oct 04; 17(10):3276-82. PubMed ID: 10506630
    [Abstract] [Full Text] [Related]

  • 18. A phase II trial of weekly high dose continuous infusion 5-fluorouracil plus oral leucovorin in patients with advanced colorectal cancer. The Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD).
    Aranda E, Cervantes A, Dorta J, Blanco E, Fernández-Martos C, Cruz-Hernandez JJ, Carrato A, Gonzalez-Mancha R, García-Conde J, Díaz-Rubio E.
    Cancer; 1995 Aug 15; 76(4):559-63. PubMed ID: 8625147
    [Abstract] [Full Text] [Related]

  • 19. Outpatient weekly high-dose continuous-infusion 5-fluorouracil plus oral leucovorin in advanced colorectal cancer. A phase II trial. Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD).
    Aranda E, Cervantes A, Carrato A, Fernández-Martos C, Antón-Torres A, Massutí T, Barneto I, García-Conde J, Barón JM, Díaz-Rubio E.
    Ann Oncol; 1996 Aug 15; 7(6):581-5. PubMed ID: 8879371
    [Abstract] [Full Text] [Related]

  • 20. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U, Wilke H, Seeber S.
    Semin Oncol; 1996 Oct 15; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.